Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH et al
Sugihara, H
Novo Nordisk is testing an IL6 inhibitor, Ziltivekimab, which cut hsCRP levels by ~80-90% in the phase 2 trial: The phase 3 trial is measuring the hard outcomes: cardiovascular death, myocardial infarction, or stroke, in people with established cardiovascular disease, chronic kidney disease, and persistent inflammation
Related Stories Researchers reveal benefits, risks linked to popular weight-loss drugs Popular diabetes, weight-loss drugs could now become even more effective Weight loss drugs linked to eating disorders and mental health issues Like these kind of feel good stories
Limitless Biotech Largest Catalog Limitless Biotech (also known as Limitless Life Nootropics) offers 90+ research-grade peptides manufactured under GMP protocols
In my opinion, this is a miserable return on investment given the billions invested and decades spent chasing tails on the wrong hypotheses